Experts discuss immunotherapy overlap, nutrition challenges, and clinical judgment with GLP-1 RA use.
Colleen McCabe, PharmD, BCOP
Advertisement
Articles by Colleen McCabe, PharmD, BCOP
Oncology pharmacists explore how GLP-1 agents intersect with cancer treatments, overlapping toxicities, and shared decision-making.
Peer Reviewed
This retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Beyond Injections: The Rise of Oral GLP-1 Therapy
3
FAQs Amid the Ongoing US Measles Outbreaks
4
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
5